Drugs / PF-05175157
last change Oct 2014 re-read 2 minutes ago

PF-05175157

Small molecule

Developed for
type 2 diabetes mellitus · acne
Investigated by
Pfizer

Trials 13 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT01819922 Apr → Oct 2013 Pfizer Completed No outcome recorded
Phase 1 NCT01807377 Apr → Aug 2013 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01821079 Mar → Apr 2013 Pfizer Completed No outcome recorded
Phase 1 NCT01757756 Oct → Nov 2012 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01537497 Mar → May 2012 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01469468 Nov → Dec 2011 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01433380 Jul 2011 → May 2012 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01396161 Jul 2011 → Feb 2012 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01274663 Nov 2010 → May 2011 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 24 trials
Phase 2 NCT02100527 Apr → Oct 2014 acne Pfizer Withdrawn No outcome recorded
Phase 2 NCT02053103 Mar → Apr 2014 type 2 diabetes mellitus Pfizer Terminated No outcome recorded
Phase 2 NCT02053116 Mar → Apr 2014 type 2 diabetes mellitus Pfizer Terminated No outcome recorded
Phase 2 NCT01792635 Dec 2012 → May 2014 type 2 diabetes mellitus Pfizer Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as PF-05175157 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01819922
12

NCT01821079

NCT01807377

NCT01537497

NCT01433380

NCT01469468

NCT02053116

NCT02053103

NCT01274663

NCT01396161

NCT01792635

NCT02100527

NCT01757756

Modality Small molecule CHEMBL3359265
Route Oral “single oral doses of PF-05175157” NCT01274663